A month has gone by since the last earnings report for Achillion Pharmaceuticals, Inc. . Shares have added about 31.1% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Achillion Reports Wider-than-Expected Loss in Q1
Achillion Pharmaceuticals reported a loss of $0.15 per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of $0.08. In the year-ago quarter, the company had reported a loss of $0.13 per share.
The company did not record any revenues in the reported quarteras well as the year-ago quarter.
Research and development expenses increased 16.5% from the year-ago period to $15.5 million due to increased clinical trial and consulting costs related to pipeline candidate ACH-4471. The increase in expenses also included preclinical and manufacturing costs related to next generation factor D inhibitor compounds in development.
General and administrative expenses were up 5.56% to $5.7 million due to an increase in corporate legal fees and consulting fees.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
Achillion Pharmaceuticals, Inc. Price and Consensus
VGM Scores
At this time, the stock has a poor Growth Score of 'F', however its momentum is doing a lot better with an 'A'. However, the stock was allocated a grade of 'F' on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregste VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for momentum based on our styles scores.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
Image: Bigstock
Achillion (ACHN) Up 31.1% Since Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Achillion Pharmaceuticals, Inc. . Shares have added about 31.1% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Achillion Reports Wider-than-Expected Loss in Q1
Achillion Pharmaceuticals reported a loss of $0.15 per share in the first quarter, wider than the Zacks Consensus Estimate of a loss of $0.08. In the year-ago quarter, the company had reported a loss of $0.13 per share.
The company did not record any revenues in the reported quarteras well as the year-ago quarter.
Research and development expenses increased 16.5% from the year-ago period to $15.5 million due to increased clinical trial and consulting costs related to pipeline candidate ACH-4471. The increase in expenses also included preclinical and manufacturing costs related to next generation factor D inhibitor compounds in development.
General and administrative expenses were up 5.56% to $5.7 million due to an increase in corporate legal fees and consulting fees.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
Achillion Pharmaceuticals, Inc. Price and Consensus
Achillion Pharmaceuticals, Inc. Price and Consensus | Achillion Pharmaceuticals, Inc. Quote
VGM Scores
At this time, the stock has a poor Growth Score of 'F', however its momentum is doing a lot better with an 'A'. However, the stock was allocated a grade of 'F' on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregste VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for momentum based on our styles scores.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.